Bionor Notice of Q1 2015 Results

Webcast and call on 13 May 2015 at 0830 CEST

(Oslo, Norway, 6 May 2015) Bionor Pharma ASA (OSE:BIONOR), a peptide vaccine company advancing the potential first therapeutic vaccine towards a functional cure for HIV, today announces that it will release its Q1 2015 results on 13 May 2015 at 0700 CEST. The announcement will be followed by a presentation for analysts and investors at 0830 CEST, hosted by David H. Solomon, CEO and Jens Krøis, CFO.

Dial-in numbers
Use the following numbers to participate in the Q&A session at the end of the presentation or listen to the webcast by telephone:

Conference call dial-ins:
Copenhagen, Denmark+45 32 71 16 60
London, United Kingdom+44 20 3427 1910
New York, USA+1 646 254 3366
Oslo, Norway+47 2316 2787
Stockholm, Sweden+468 5065 3937
Conference code: 2066073

The presentation will be made available at the time of the webcast at:

The webcast will be available for replay up to one week after the presentation on the following numbers:

Webcast replay:
Copenhagen, Denmark+45 32 71 09 13
London, United Kingdom+44 20 3427 0598
New York, USA+1 347 366 9565
Oslo, Norway+47 2100 0498
Stockholm, Sweden+468 5051 3897
Replay passcode: 2066073

The quarterly report and presentation will be made available both OSE and the Company’s website at 0700 CEST

Notes to Editors

About Bionor
Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company’s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV.

Bionor Pharma’s current clinical development pipeline comprises two vaccine candidates for the treatment of HIV, Vacc-4x and Vacc-C5. Vacc-4x is the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Bionor Pharma’s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through a collaboration with Celgene Corp, is investigating Vacc-4x and romidepsin in the REDUC study.

Bionor is listed on the Oslo stock exchange, under the ticker BIONOR.

More information about Bionor is available at

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

For more information please contact:
Bionor Pharma ASA
President and Chief Executive Officer
David Solomon: Tel +00 47 23 01 09 60

Consilium Strategic Communications
Mary-Jane Elliott / Ivar Milligan / Jessica Hodgson / Hendrik Thys
+44 (0)20 3709 5700